ArticleEClinicalMedicine2023

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.

John Marsden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.